Data that were presented at the International Stroke Conference 2021 adds to the literature on the efficacy and safety of endovascular thrombectomy in patients with large vessel occlusion presenting more than 24 hours from last known...
Data that were presented at the International Stroke Conference 2021 adds to the literature on the efficacy and safety of endovascular thrombectomy in patients with large vessel occlusion presenting more than 24 hours from last known...
Tenecteplase was associated with lower rates of symptomatic intracranial hemorrhage than alteplase, according to preliminary study findings presented at ISC 2022.
Tenecteplase was associated with lower rates of symptomatic intracranial hemorrhage than alteplase, according to preliminary study findings presented at ISC 2022.
Management of unruptured arteriovenous malformations (AVMs) has changed since the publishing of the ARUBA trial findings, according to data presented at ISC 2022.
Management of unruptured arteriovenous malformations (AVMs) has changed since the publishing of the ARUBA trial findings, according to data presented at ISC 2022.
According to research presented at the International Stroke Conference 2022, the proportion of platelets in intracranial thrombus is an independent marker of first pass recanalization (FPR).
According to research presented at the International Stroke Conference 2022, the proportion of platelets in intracranial thrombus is an independent marker of first pass recanalization (FPR).
As presented in an abstract at the International Stroke Conference 2022, researchers found that the use of endovascular stroke therapy (EVT) was associated with excellent clinical outcomes and population-level improvements in acute ischemic...
As presented in an abstract at the International Stroke Conference 2022, researchers found that the use of endovascular stroke therapy (EVT) was associated with excellent clinical outcomes and population-level improvements in acute ischemic...
New findings published in JAMA Neurology suggest that noncontrast computed tomography (CT) can be an imaging alternative to select patients with late-presenting large-vessel occlusion for mechanical thrombectomy.
New findings published in JAMA Neurology suggest that noncontrast computed tomography (CT) can be an imaging alternative to select patients with late-presenting large-vessel occlusion for mechanical thrombectomy.
Mark J. Alberts, MD, FAHA, FAAN, reviewed recent research on the treatment of transient ischemic attack and minor stroke during a virtual presentation for Neurology Week.
Mark J. Alberts, MD, FAHA, FAAN, reviewed recent research on the treatment of transient ischemic attack and minor stroke during a virtual presentation for Neurology Week.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
Adding the anti-clotting drugs argatroban or eptifibatide to routine intravenous thrombolysis treatment in patients with acute ischemic stroke did not reduce poststroke disability, and was associated with an increase in mortality.
Adding the anti-clotting drugs argatroban or eptifibatide to routine intravenous thrombolysis treatment in patients with acute ischemic stroke did not reduce poststroke disability, and was associated with an increase in mortality.
In patients with acute ischemic stroke eligible for intravenous thrombolysis within 4.5 hours of symptom onset, tenecteplase was noninferior to alteplase for achieving an excellent functional outcome at day 90.
In patients with acute ischemic stroke eligible for intravenous thrombolysis within 4.5 hours of symptom onset, tenecteplase was noninferior to alteplase for achieving an excellent functional outcome at day 90.
At the SNIS 21st Annual Meeting, Radical Catheter Technologies presented their Neurovascular Radical Catheter, which obtained 510(k) clearance from the US FDA FDA for its novel endovascular technology.
At the SNIS 21st Annual Meeting, Radical Catheter Technologies presented their Neurovascular Radical Catheter, which obtained 510(k) clearance from the US FDA FDA for its novel endovascular technology.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.
Prestroke single and dual antiplatelet therapy are associated with an increased risk of symptomatic intracerebral hemorrhage after treatment with intravenous alteplase for acute ischemic stroke.
Prestroke single and dual antiplatelet therapy are associated with an increased risk of symptomatic intracerebral hemorrhage after treatment with intravenous alteplase for acute ischemic stroke.
Intravenous tirofiban decreased the risk of early neurological deterioration in patients with acute noncardioembolic stroke without an increased risk of symptomatic intracerebral hemorrhage or systematic bleeding, according to study results...
Intravenous tirofiban decreased the risk of early neurological deterioration in patients with acute noncardioembolic stroke without an increased risk of symptomatic intracerebral hemorrhage or systematic bleeding, according to study results...
Anticoagulation therapy in patients with cervical artery dissection was associated with a lower combined rate of 90-day ischemic stroke, major bleeding, or death compared with antiplatelet therapy, according to results published in JAMA...
Anticoagulation therapy in patients with cervical artery dissection was associated with a lower combined rate of 90-day ischemic stroke, major bleeding, or death compared with antiplatelet therapy, according to results published in JAMA...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click